Lantern Pharma (NASDAQ: LTRN), a clinical-stage, AI-driven precision oncology company, has received regulatory and Institutional Review Board (IRB) approvals in Taiwan to open Part 2 of its Phase 2 HARMONIC trial of LP-300, according to a press release. The lead Taiwan site is now open to accrual and actively screening patients, with Lantern anticipating IRB approval at two additional sites during the fourth quarter. In the United States, a central IRB has approved the amended protocol, and clinical sites have begun identifying patients with the EGFR exon 21 L858R mutation. This regulatory progress marks a significant step for Lantern’s AI-guided approach to oncology drug development, potentially bringing a new treatment option to a patient population with limited effective therapies after tyrosine kinase inhibitor (TKI) resistance.
Part 2 of the HARMONIC trial will enroll patients with the L858R mutation who have progressed after TKI treatment. The amended protocol allows LP-300 to be administered for up to eight cycles in combination with carboplatin and pemetrexed, up from six cycles previously. Preliminary data showed median progression-free survival of 8.9 months among nine L858R patients who completed six cycles, compared with 8.3 months among all 16 L858R patients evaluated. The company emphasized that these findings are preliminary, exploratory, and based on small patient numbers. For a full view of the press release, visit https://ibn.fm/CqeDR.
The implications for the biotech and AI sectors are noteworthy. Lantern Pharma leverages its proprietary RADR artificial intelligence and machine-learning platform to transform the cost, pace, and precision of oncology drug development. By integrating large-scale genomic and biological data with advanced machine learning, RADR is designed to identify patients most likely to benefit from Lantern’s therapies and to guide biomarker-driven clinical development. This approach could reduce the time and expense of bringing new cancer drugs to market, a critical advantage as the industry faces increasing pressure to deliver targeted therapies efficiently. Lantern’s pipeline includes LP-184 (zirdafulven), LP-300, and LP-284, along with its central-nervous-system-focused subsidiary, Starlight Therapeutics, and its AI subsidiary, Open-Medicine AI. For ongoing updates on LTRN, visit the company’s newsroom at https://ibn.fm/LTRN.
The broader impact extends to investors and industry watchers tracking AI’s role in drug discovery. Successful expansion of the HARMONIC trial could validate RADR’s predictive capabilities, encouraging further investment in AI-driven precision medicine. BioMedWire, a specialized communications platform focused on biotechnology, biomedical sciences, and life sciences, is one of more than 75 brands within the Dynamic Brand Portfolio at IBN. The platform provides access to a vast network of wire solutions via InvestorWire, article and editorial syndication to 5,000+ outlets, and enhanced press release enhancement. For more information about BioMedWire, visit BioMedWire.
